Dr. Scott M. Rocklage is a former pharmaceutical executive that brings over 30 years of research and development experience to 5AM Ventures as one of its three managing partners. 5AM Ventures is a venture capitalist firm that provides support to companies providing medical and scientific breakthroughs to offer solutions and preventive care for numerous medical conditions.
Prior to joining 5AM Ventures in 2003 as a Venture Partner, Dr. Rocklage held numerous leadership roles as the Chief Executive Officer of Cubist Pharmaceuticals (acquired by Merck), Nycomed Salutar, EPIRUS Biopharmaceuticals, and Amersham Health. In addition to his roles as CEO, he has served as the Director at EPIRUS Biopharmaceuticals, Relypsa (acquired by Vifor Pharma), VBI Vaccines, Cubist Pharmaceuticals, Achaogen, MDS Proteomics, and Protana. Board membership includes former Chairman at Archaogen, Illypsa (acquired by Amgen), Miikana (acquired by EntreMed), and Semprus (acquired by Teleflex). Dr. Rocklage currently serves as the Board Chairman of Rennovia, Kinestral, and Cidara.
His extensive knowledge in healthcare management coupled with excellence in leadership has allowed Dr. Rocklage to obtain FDA approval of three new U.S. drug applications (Omniscan™, Teslascan®, and Cubicin®). Other accolades include creator and co-creator of more than 30 U.S. patents as well the author of 100+ peer-reviewed publications.
Dr. Rocklage’s formal education includes a B.S. in Chemistry from the University of California, Berkeley and Ph.D. in Chemistry from the Massachusetts Institute of Technology (MIT), where Dr. Scott Rocklage conducted research in Nobel Prize winner Richard R. Schrock’s laboratory. Dr. Rocklage is currently based in 5AM Ventures’ Boston location.
To learn more, visit http://5amventures.com/team/scott-m-rocklage-phd/.